Key Highlights

  • Rocket Pharmaceuticals shares closed up 10% at $3.41.
  • The company announced a clinical safety update for the first three patients treated under a modified protocol for RP-A501.
  • No instances of thrombotic microangiopathy or capillary leak syndrome were observed.
  • Rocket is engaging with the FDA to establish a pathway to treat the remaining patients in the 12-subject cohort.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares closed up 10% at $3.41 after the company announced a clinical safety update for the initial three patients treated under a modified protocol in its pivotal Phase 2 trial evaluating RP-A501, an investigational gene therapy for Danon disease.

What Happened

Patients received a recalibrated dose of 3.8 times 10^13 GC/kg alongside a refined immunomodulatory regimen, which was well tolerated, with no instances of thrombotic microangiopathy (TMA) or capillary leak syndrome observed.

Market Reaction

Shares rose 10% following the encouraging early safety signals, reflecting positive investor response to the absence of the serious adverse events that had previously been a key safety concern for the therapy.

Outlook

Following these encouraging early safety signals, Rocket is actively engaging with the FDA to establish a pathway to treat the remaining patients in the 12-subject cohort and anticipates providing a comprehensive regulatory and program update in the second half of 2026.

Why did Rocket Pharmaceuticals shares rise 10%?

Shares rose after the company reported positive early safety data for RP-A501 under a modified protocol, with no instances of TMA or capillary leak syndrome.

What is RP-A501?

An investigational gene therapy for Danon disease.

What is Rocket's next step with the FDA?

The company is engaging with the FDA to establish a pathway to treat the remaining patients in the 12-subject cohort, with a comprehensive update expected in the second half of 2026.